Everything below concerns Nuclear receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-03-18. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
| Property | Value | Notes |
|---|---|---|
| WADA classification | S4 Hormone and Metabolic Modulators | Prohibited at all times in sport. |
| Drug approval status | Not approved in major jurisdictions | No accepted therapeutic indication. |
| Common detection method | LC-MS/MS | Detects parent compound and metabolites. |
| Typical test matrix | Urine or blood | Urine is common in anti-doping testing. |
| Product labeling | Research chemical or supplement | Often not independently verified. |
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
== Historical development == Early experiments resembling activity-based profiling were conducted in the 1970s, when small molecules were used to study the mechanism of action of the serine-modifying antibiotic penicillin. The modern era of ABPP began in the 1990s with the development of ABPs compatible with proteomic workflows, and the first applications of ABPP were reported during this decade in studies of proteases. In 1999, the Cravatt lab formally introduced the term "activity-based protein profiling," establishing a framework for systematic functional proteomics. Subsequent work by Ben Cravatt at The Scripps Research Institute, Matthew Bogyo at Stanford University, and Herman S. Overkleeft at Leiden University helped define the field through the design of probes targeting serine hydrolases, cysteine proteases, oxidoreductases, human cytochrome P450s and other enzyme families. Since its inception, ABPP has expanded rapidly, with bibliometric analyses documenting exponential growth in publications and widespread adoption across North America, Europe, and Asia. Advances in mass spectrometry and protein separation technologies further accelerated the integration of ABPP into proteomic research, enabling the characterization of enzyme activity on a global scale and establishing ABPP as a cornerstone of functional proteomics.
=== Industrial discharge === Industrial discharge is when waste products are released into the environment from manufacturing and chemical processing facilities. This waste can include a wide variety of CEC like heavy metals, solvents, and various organic compounds that are not regularly detected for or removed by standard treatment processes. These contaminants can accumulate in sediments and biota, posing risks to aquatic life and human health. The complexity and diversity of industrial discharge requires advanced treatment technologies and stricter regulatory frameworks to prevent CEC from contaminating the environment. Advanced oxidation processes and membrane technologies have been researched and shown to reduce CEC from industrial discharge, however there is an excessive cost to retrofit existing treatment facilities with this technology.
== Fascia research == In 2007, Schleip along with Werner Klingler organized the first Fascia Research Congress, sponsored by the National Institute of Health and hosted at Harvard Medical School. The conference was covered in a two-page Science Magazine article titled "Cell Biology Meets Rolfing with a section titled "From Rolfer to Researcher" referring to Schleip's career shift. He has served on the scientific committee for all subsequent congresses (2009, 2012, 2015, 2018, 2022, 2025) and chaired the 2018 and 2022 congresses. He was a founding member of the Fascia Research Society in 2011 and has served on the board of directors since 2020. In 2023 he received the designation of founding director. Schleip is the director of the Fascia Research Group, a research collaboration between the University of Ulm (2007-2019) and the Technical University of Munich (2019-Present). He is co-founder and co-director of the Institute für Angewandte & Integrative Gesundheitsforschung (IAIG), a research institute directed towards applied and integrative health research under the umbrella of the Diploma University of Applied Sciences in Germany (2024–present).
Sources: en.wikipedia.org
== External links == National Center for Voice and Speech's official website Lewcock, Ronald, et al. "Acoustics: The Voice." In Grove Music Online (by subscription)/ http://www.oxfordmusiconline.com/subscriber/article/grove/music/00134pg6
== Historical understanding == Historically, there has been much dispute over whether such a thing as a vacuum can exist. Ancient Greek philosophers debated the existence of a vacuum, or void, in the context of atomism, which posited void and atom as the fundamental explanatory elements of physics. Lucretius argued for the existence of vacuum in the first century BC and Hero of Alexandria tried unsuccessfully to create an artificial vacuum in the first century AD. Following Plato, however, even the abstract concept of a featureless void faced considerable skepticism: it could not be apprehended by the senses, it could not, itself, provide additional explanatory power beyond the physical volume with which it was commensurate and, by definition, it was quite literally nothing at all, which cannot rightly be said to exist. Aristotle believed that no void could occur naturally, because the denser surrounding material continuum would immediately fill any incipient rarity that might give rise to a void. In his Physics, book IV, Aristotle offered numerous arguments against the void: for example, that motion through a medium which offered no impediment could continue ad infinitum, there being no reason that something would come to rest anywhere in particular. In the medieval Muslim world, the physicist and Islamic scholar Al-Farabi wrote a treatise rejecting the existence of the vacuum in the 10th century. He concluded that air's volume can expand to fill available space, and therefore the concept of a perfect vacuum was incoherent.
=== August === 1 August Nationwide reports that house prices fell by 3.8% in July, the sharpest decline since July 2009. The UK's first permanent drone delivery service begins, with Royal Mail and Skyports establishing a daily inter-island mail distribution between three islands on Orkney. Changes on excise duty for alcohol come into force, with the tax levied depending on a drink's strength. Former SNP MP Margaret Ferrier loses her seat, following a successful recall petition, triggering a by-election. 2 August – COVID-19 in the UK: The UK Health Security Agency reports the spread of a new variant known as EG.5.1. 3 August The National Risk Register publishes its latest report on future threats facing the UK. It puts the chance of another pandemic at between 5% and 25%. Other risks include extreme weather caused by worsening climate change, advances in artificial intelligence (AI) systems, terrorism such as cyberattacks on infrastructure, and the assassination of public figures. Greenpeace activists climb onto the roof of Rishi Sunak's North Yorkshire home, unfurling sheets of black fabric, in protest at his recent decision to expand oil and gas production in the North Sea. The Bank of England raises its baseline interest rate from 5% to 5.25%, the 14th consecutive increase and the highest level since April 2008. The Bank also predicts inflation to fall below 5% in the final quarter of 2023. Brexit: Checks on fresh food from the EU are delayed for a fifth time, amid concerns over red tape.
eV, higher than what is predicted in theory for continuum plates of the same thickness, due to nonlocal microstructural constraints such as nonlocal coupling of particle rotational degrees of freedom. On the other hand, resistance to bending is found to be greatly reduced in nanoparticle monolayers that are supported at the air/water interface, possibly due to screening of ligand interactions in a wet environment.
Sources: en.wikipedia.org
== Function == Msr is ubiquitous and highly conserved. Human and animal studies have shown the highest levels of expression in kidney and liver. It carries out the enzymatic reduction of methionine sulfoxide (MetO), the oxidized form of the amino acid methionine (Met), back to methionine, using thioredoxin to catalyze the enzymatic reduction and repair of oxidized methionine residues. Its proposed function is thus the repair of oxidative damage to proteins to restore biological activity. Oxidation of methionine residues in tissue proteins can cause them to misfold or otherwise render them dysfunctional.
It appears that these effects are sequence-specific; as in most cases, if a Morpholino is associated with non-target effects, the 4-base mismatch Morpholino will not trigger these effects. A cause for concern in the use of Morpholinos is the potential for "off-target" effects. Whether an observed morphant phenotype is due to the intended knockdown or an interaction with an off-target RNA can often be addressed in embryos by running another experiment to confirm that the observed morphant phenotype results from the knockdown of the expected target. This can be done by recapitulating the morphant phenotype with a second, non-overlapping Morpholino targeting the same mRNA, by confirmation of the observed phenotypes by comparing with a mutant strain (though compensation will obscure a phenotype in some mutants), by testing the Morpholino in a null mutant background to detect additional phenotypic changes or by dominant-negative methods. As mentioned above, rescue of observed phenotypes by coinjecting a rescue mRNA is, when feasible, a reliable test of specificity of a Morpholino.
Christine Helen Foyer (born 3 October 1952) is professor of plant science at the University of Birmingham, Birmingham, UK. She is President Elect of the Association of Applied Biologists, the General Secretary of the Federation of European Societies of Plant Biologists, an elected Board Member of the American Society of Plant Biologists and a Member of the French Academy of Agriculture. She has published and co-authored many papers on related subjects. Foyer's name is included in the "Foyer–Halliwell–Asada" pathway, a cellular process of hydrogen peroxide metabolism in plants and animals and named for the three principal discoverers.
Sources: en.wikipedia.org
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.
Legality varies by country and context. It lacks marketing approval as a medicine in major countries. Sports organizations prohibit its use at all times.
A certificate of analysis may report identity, purity, and testing methods for a specific batch. It does not guarantee safety or legal status. Independent verification can confirm whether the material matches the label.
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.